Personalized Medicine: The Emerging Pharmacogenomics Revolution
Presented by PricewaterhouseCoopers

Revolutionary change requires new ways of thinking. Pharmacogenomics, the next fundamental development in human medicine, promises to usher in an era of personalized medicine. Hear a distinguished panel of speakers explore new strategic options and their impacts on patients, established companies, emerging companies, and payers all of whom are linked through emerging business models.

Moderator:
Gerald McDougall, Partner-in-Charge, Health Sciences Practice PriceWaterhouseCoopers LLP

Speakers:

Bill Hearl, PhD.
Chief Scientific Officer
Capital Genomix, Inc.

Bill provides perspectives from his experiences in a small biotech company and through my network of peers and associates in the industry. He has worked in biotechnology for almost 20 years in a variety of environment starting in diagnostics with Pharmacia (ENI) and HIV blood tests, IGEN, Life Technologies (Invitrogen), KPL and finally founded Capital Genomix in 2000. Capital Genomix is working to develop biomarkers for cancer derived from clinically characterized patients. Their process is termed "patient driven drug discovery" and is based on the idea of using well characterized patient samples that are sequentially examined for chemo-sensitivity and genomic profiles followed by the identification of novel targets (proteins). Other proprietary platform technologies are then used to develop antibodies that can be screened back against patient samples for reactivity. The goal is to help sub-divide the patient population based on these biomarkers to facilitate the best therapy course and prognosis.

David Weinreich, M.D., M.B.A.
Vice President Clinical Affairs
Gene Logic Inc.

Dr. Weinreich comes from the National Cancer Institute (NCI) where he was Director of the Laboratory of Surgical Metabolism and a principal investigator on numerous clinical trials. Dr. Weinreich's has conducted both bench research and clinical trials in multiple therapeutic areas including oncologic vaccines, adoptive cellular therapies, anti-angiogenics and small molecules and has participated in excess of 50 clinical trials during his tenure at the NCI. Dr. Weinreich spearheaded the use of IL-1ra as a potential anti-angiogenic from concept through to clinical trials that remain ongoing at this time. Dr. Weinreich has also served as consultant to several small and large biotechnology companies assisting them in developing clinical plans leading to drug approval. Dr. Weinreich has completed fellowships in Immunotherapy and Oncology/Surgical Oncology from the National Cancer Institute and has his M.D. from Boston University (AOA honors) and his M.B.A. from the McDonough School of Business at Georgetown University. At Gene Logic, Dr. Weinreich runs the clinical services division whose primary mission is to provide pharmacogenomic solutions and diagnostic tests to our pharmaceutical partners during the clinical phase of drug development.

Joseph J. Carangelo, MBA
Director, Strategic Planning and Business Development
Gen-Probe Inc.

Joe is a Director in Strategic Planning and Business Development at Gen-Probe Incorporated, a Growth Company in the area of Molecular Diagnostics and a Leader in Nucleic Acid Technology based in San Diego. At Gen-Probe he is responsible for strategy development in emerging areas, as well as identifying, evaluating, and negotiating growth opportunities consistent within those strategies. He was an early architect of Gen-Probe's Oncology Strategy and was instrumental in the exclusive in-licensing of the PCA3 gene enabling the company's flagship effort in the area, the development of a novel genomic-based assay in the diagnosis of prostate cancer. He is currently taking a leadership role in developing Gen-Probe's strategy in Personalized Medicine, currently under development. Joe has greater than 12 years experience in the diagnostic biotechnology arena. Previously to Gen-Probe, Joe held Strategic Marketing, Strategic Planning, and Business Development positions at Hybritech, an Oncology Diagnostic biotech company, and as a Management Consultant. Joe has a BS in Chemical Engineering from the Massachusetts Institute of Technology, a MS in Chemical Engineering from the University of California at Berkeley, and a Masters in Business Administration from the Stanford Graduate School of Business.